文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

TAVI 术后抗凝单药与抗血小板单药比较:ACASA-TAVI 随机临床试验

Anticoagulation Monotherapy vs Antiplatelet Monotherapy After Transcatheter Aortic Valve Implant: The ACASA-TAVI Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-08-30

该前瞻性、随机、开放标签、盲法终点试验在挪威 3 家中心纳入 360 例 65 至 80 岁因重度主动脉瓣狭窄接受 TAVI 的患者,1:1 随机接受 12 个月 NOAC 或 ASA 单药治疗。

要点

  • TAVI 术后 NOAC 单药较 ASA 单药降低 12 个月 HALT 发生率。
  • NOAC 组出血、血栓栓塞事件或全因死亡复合终点不劣于 ASA 组。
  • 结论支持在部分筛选患者中 TAVI 术后采用抗凝治疗。

核心结论

  • TAVI 术后 NOAC 单药策略降低 HALT 发生率,且在出血、血栓栓塞事件或死亡方面不劣于 ASA 单药。
  • 研究提示抗凝治疗可能使部分 TAVI 患者获益。

研究设计与样本

  • 前瞻性、随机、开放标签、盲法终点试验,2021 年 12 月至 2025 年 6 月在挪威 3 家中心开展。
  • 360 例 65 至 80 岁因重度主动脉瓣狭窄接受 TAVI 的患者按 1:1 随机接受 12 个月 NOAC 或 ASA 单药。
  • 平均年龄 74.5 岁(SD 3.7),女性 134 例(37%);336 例完成试验(每组 168 例)。

主要发现

  • 主要疗效终点 12 个月盲法核心实验室 4 维心脏 CT 显示的 HALT:NOAC 组 27 例(16.2%),ASA 组 48 例(28.6%)。
  • 主要安全终点(VARC-3 出血事件、血栓栓塞事件与全因死亡复合):NOAC 组 13 例(7.5%),ASA 组 19 例(10.6%)。

关键数值与推荐

  • 主要疗效终点为 12 个月盲法核心实验室 4 维心脏 CT 上的 HALT。
  • 主要安全终点为裁定的 VARC-3 出血事件、血栓栓塞事件与全因死亡复合终点(12 个月)。

临床怎么用

  • 对 TAVI 术后患者,可考虑 NOAC 单药替代 ASA 单药以降低 HALT 风险。
  • 决策需结合患者出血与血栓风险,本研究仅支持在筛选人群中的应用。

局限性

  • 开放标签设计,仅 3 家挪威中心开展。
  • 样本量 360 例,随访 12 个月,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Transcatheter aortic valve implant (TAVI) is increasingly being performed in younger and healthier patients with severe aortic valve stenosis. Antithrombotic therapy after TAVI is a key element of optimizing valve durability and clinical outcomes. OBJECTIVE: To evaluate the safety and efficacy of a factor Xa inhibitor non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy strategy vs an acetylsalicylic acid (ASA) monotherapy strategy after TAVI. DESIGN, SETTING, AND PARTICIPANTS: Between December 2021 and June 2025, 360 participants between the ages of 65 and 80 years undergoing TAVI for severe aortic valve stenosis were enrolled in this prospective, randomized, open-label, blinded end point trial conducted at 3 Norwegian centers managing the majority of TAVI procedures nationally. The last patient completed follow-up on May 19, 2026. INTERVENTION: A total of 360 participants were randomly assigned (1:1) to receive 12 months of monotherapy with either NOAC (intervention) or ASA (control). MAIN OUTCOMES AND MEASURES: A predefined co-primary end point strategy was chosen to address both efficacy and safety. The primary efficacy end point was TAVI valve leaflet thrombosis defined as the presence of hypoattenuated leaflet thickening (HALT) on blinded core laboratory 4-dimensional cardiac computed tomographic (CT) scan at 12 months. The primary safety end point was a composite of adjudicated Valve Academic Research Consortium 3 (VARC-3) bleeding events, thromboembolic events, and all-cause death at 12 months. RESULTS: Of the 360 participants randomized (mean age, 74.5 years [SD, 3.7]; 134 females [37%]), 336 completed the trial (168 in each group). The primary efficacy end point occurred in 27 participants (16.2%) allocated to the NOAC group and in 48 participants (28.6%) allocated to the ASA group (risk ratio, 0.55; 95% CI, 0.37 to 0.82, P = .004). The primary safety end point occurred in 13 participants (7.5%) in the NOAC group and in 19 participants (10.6%) in the ASA group (risk difference, -3.3%; 95% CI, -9.5% to 2.8%; P for noninferiority <.001). CONCLUSIONS AND RELEVANCE: A strategy of NOAC monotherapy after TAVI reduced the incidence of HALT and was noninferior for bleeding, thromboembolic events, or death compared with acetylsalicylic acid monotherapy. These findings suggest that anticoagulation therapy can be beneficial after TAVI in selected patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05035277.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Dodgson CS, Herstad J, Kløve SF, et al. Anticoagulation Monotherapy vs Antiplatelet Monotherapy After Transcatheter Aortic Valve Implant: The ACASA-TAVI Randomized Clinical Trial. JAMA. 2026. PMID: 42669043. doi:10.1001/jama.2026.17036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。